Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Press releases
Our latest press releases
Hansa Biopharma Announces New Board Appointments
Regulatory press release
24/09/2026
Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ)
Regulatory press release
22/09/2026
Hansa Biopharma to participate in LSX Congress USA in Boston
21/09/2026
Hansa Biopharma participating in Pareto Securities’ 17th Annual Healthcare Conference 2026
27/08/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
